ACTR-18. PHASE II TRIAL OF TEMOZOLOMIDE AND TRC 102, BASE EXCISION REPAIR INHIBITOR, IN BEVACIZUMAB NAÏVE GLIOBLASTOMA AT FIRST RECURRENCE

BACKGROUND: Temozolomide forms O(6)-methylguanine (O(6)mG), 7-methylguanine (N(7)mG), and 3- methyladenine (N(3)mA) DNA adducts. The O(6)mG DNA adduct is repaired by MGMT. N(7)mG and N(3)mA DNA adducts are removed by the base excision repair (BER) pathway. TRC-102 is a BER inhibitor that binds to th...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Ahluwalia, Manmeet, Drappatz, Jan, Ye, Xiaobu, Walbert, Tobias, Holdhoff, Matthias, Lesser, Glenn, Cloughesy, Tim, Peereboom, David, Burt Nabors, L, Wen, Patrick, Grossman, Stuart, Rogers, Lisa
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2018
Matèries:
Abstracts
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6216166/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.052
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars